Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells

The aims of this study were to determine whether combination chemotherapeutics exhibit a synergistic effect on breast cancer cell metabolism. Palbociclib, is a selective inhibitor of cyclin-dependent kinases 4 and 6, and when patients are treated in combination with fulvestrant, an estrogen receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Warth, Benedikt, Palermo, Amelia, Rattray, Nicholas J.W., Lee, Nathan V., Zhu, Zhou, Hoang, Linh T., Cai, Yuping, Mazurek, Anthony, Dann, Stephen, VanArsdale, Todd, Fantin, Valeria R., Shields, David, Siuzdak, Gary, Johnson, Caroline H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359333/
https://www.ncbi.nlm.nih.gov/pubmed/30609717
http://dx.doi.org/10.3390/metabo9010007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359333/
https://www.ncbi.nlm.nih.gov/pubmed/30609717
http://dx.doi.org/10.3390/metabo9010007

Ejemplares similares